New molecular information from blood is being used to improve patient outcomes. Assays for established biomarkers have recently advanced (so-called high sensitivity, variants and ultra, for examples), allowing physicians to use this additional information to provide better care. The enhanced patient outcomes result from more detailed, accurate and precise diagnostic and risk stratification, resulting in more timely and useful care (such as pharmaceuticals, treatments options, and timing of treatments) and avoiding unnecessary and costly actions. The objective of this proposal is to enable a new capability to isolate and concentrate biomarkers from blood in small volumes (200 microliters), at high sensitivity, over short periods of time, and to monitor multiple markers. We initially will focus on biomarkers for myocardial infarction and stroke. Upon completion of the entire projectwhich this proposal enablesenhanced information will be provided to physicians, allowing for accurate and fast diagnostics and treatments providing better patient outcomessaving lives and money. To accomplish the proposal objective, a pair of microfluidic techniques will allow processing of small samples of blood to remove unwanted materials and isolate and concentrate the target biomarkers. These two techniques enable the objective because they keep the sample volume minimal and remove unwanted materials that could degrade detection, while quickly isolating and concentrating target species. Physically, this is made possible by exploit a unique combination of dielectrophoretic, flow and electrophoretic forces combined into the two techniques (gradient dielectrophoresis and electrophoretic capture) pioneered in the PIs laboratory. Gradient dielectrophoresis will remove cells and debris (and perhaps concentrate the targets) and electrophoretic capture will isolate and concentrate individual biomarkers away from possible interfering species. The four target biomarkers identified for proof of principle to enable the larger project are: two cardiac markers myoglobin and cardiac troponin I, (cTnI), a stroke markerneuron specific enolase (NSE), and an inflammatory markertumor necrosis factor-alpha (TNFa). These targets will provide a reasonable test for the success of the strategy and techniques
|Effective start/end date||7/1/10 → 6/30/13|
- HHS: National Institutes of Health (NIH): $415,084.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.